Patents by Inventor Holly Mead

Holly Mead has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Dendritic cell-specific antibody conjugate comprising anti-CD40 monoclonal antibodies conjugated to HIV-1 Gag/Nef
    Patent number: 9109011
    Abstract: The present invention includes compositions and methods for making and using a vaccine that includes a DC-specific antibody or fragment thereof to which an engineered Gag antigen is attached to form an antibody-antigen complex, wherein the Gag antigen is less susceptible to proteolytic degradation by eliminating one or more proteolytic sites or a DC-specific antibody or fragment thereof to which an engineered Nef antigen is attached to form an antibody-antigen complex, wherein the Nef antigen comprises one or more codon usage optimization that increase antibody-antigen complex secretion, or both, wherein the vaccine is able to elicit an HIV-specific T cell immune response to Gag p17, Gag p24, Nef and/or Cyclin D1.
    Type: Grant
    Filed: July 16, 2009
    Date of Patent: August 18, 2015
    Assignee: Baylor Research Institute
    Inventors: Jacques F. Banchereau, Gerard Zurawski, Anne-Laure Flamar, Amanda Cobb, Holly Mead, Monica Montes, Sandra Zurawski, SangKon Oh
  • HIV VACCINE BASED ON TARGETING MAXIMIZED GAG AND NEF TO DENDRITIC CELLS
    Publication number: 20100135994
    Abstract: The present invention includes compositions and methods for making and using a vaccine that includes a DC-specific antibody or fragment thereof to which an engineered Gag antigen is attached to form an antibody-antigen complex, wherein the Gag antigen is less susceptible to proteolytic degradation by eliminating one or more proteolytic sites or a DC-specific antibody or fragment thereof to which an engineered Nef antigen is attached to form an antibody-antigen complex, wherein the Nef antigen comprises one or more codon usage optimization that increase antibody-antigen complex secretion, or both, wherein the vaccine is able to elicit an HIV-specific T cell immune response to Gag p17, Gag p24, Nef and/or Cyclin D1.
    Type: Application
    Filed: July 16, 2009
    Publication date: June 3, 2010
    Applicant: BAYLOR RESEARCH INSTITUTE
    Inventors: Jacques F. Banchereau, Gerard Zurawski, Anne-Laure Flamar, Amanda Cobb, Holly Mead, Monica Montes